CSAClinical-Stage Asset Intelligence
Catalyst calendar Get the data
Home / Gilead Sciences, INC. (GILD) / sacituzumab govitecan hziy
Forward catalyst · GILD

sacituzumab govitecan hziy

Sponsor Gilead Sciences, INC. · listed as GILD

READOUT Phase 3 Confidence: medium Source: clinicaltrials

sacituzumab govitecan hziy is a clinical-stage drug asset sponsored by Gilead Sciences, INC., listed as GILD. CSA tracks 3 forward catalysts for it — the nearest is a readout expected Dec 2026 (month precision, medium confidence), tied to trial NCT04639986. The asset is in Phase 3 and currently active not recruiting, studied in Metastatic Breast Cancer. It appears across 7 tracked trials in the CSA sample.

Next catalyst

Event typeREADOUT
Expected date2026-12-31
As disclosedDec 2026
Date precisionmonth
Confidencemedium
Verify at source →

Trial & sponsor

Trial (NCT)NCT04639986
PhasePHASE3
StatusACTIVE_NOT_RECRUITING
Lead sponsorGilead Sciences
Listed asGILD
Condition(s)Metastatic Breast Cancer

All tracked catalysts for sacituzumab govitecan hziy

DateEventConfidenceTrial
2026-12-31READOUTmediumNCT04639986
2027-02-28READOUTmediumNCT05382286
2027-06-30READOUTmediumNCT05633654
!

Data, not investment advice. CSA is information, not a recommendation to buy, sell or hold any security. Estimated catalyst dates routinely slip and are graded by confidence — verify against the source link before acting.

This is one row of the free CSA sample. The full snapshot carries 2,103 forward catalysts across 139 listed sponsors.

Get the full dataset — $499 →   More GILD catalysts